Pancreatic cancer cells express CD44 variant 9 and multidrug resistance protein 1 during mitosis

Experimental and Molecular Pathology

Volumn 98, Issue 1, 2015, Pages 41-46

  Kiuchi, Shizuka ^a   Ikeshita, Shunji ^a   Miyatake, Yukiko ^a   Kasahara, Masanori ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD44; MDR1; Pancreatic cancer

Indexed keywords

CD44V9 ANTIGEN; LYMPHOCYTE ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ABCB1 PROTEIN, HUMAN; HERMES ANTIGEN; MULTIDRUG RESISTANCE PROTEIN;

ANAPHASE; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CELL SURFACE; CYTOKINESIS; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; INTERPHASE; MESENCHYME CELL; METAPHASE; MITOSIS; PANCREATIC CANCER CELL LINE; PHENOTYPIC VARIATION; PROPHASE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TELOPHASE; UPREGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

AGOUTI PACA;

ANTIGENS, CD44; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MITOSIS; P-GLYCOPROTEINS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84919952064     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.12.001     Document Type: Article

References (31)

1. Adikrisna R., et al. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology 2012, 143. (234-45.e7).
2. Apodaca G., et al. Role of membrane traffic in the generation of epithelial cell asymmetry. Nat. Cell Biol. 2012, 14:1235-1243.
3. Brown R.L., et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest. 2011, 121:1064-1074.
4. Burris H.A., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
5. Fu D., Arias I.M. Intracellular trafficking of P-glycoprotein. Int. J. Biochem. Cell Biol. 2012, 44:461-464.
6. Fu D., et al. Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: Implications in multidrug resistance in cancer. Int. J. Cancer 2004, 109:174-181.
7. García-Silva S., et al. Stem cells & pancreatic cancer. Pancreatology 2013, 13:110-113.
8. Hirata K., et al. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br. J. Cancer 2013, 109:379-386.
9. Huntly B.J., Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. Cancer 2005, 5:311-321.
10. Ishimoto T., et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19:387-400.
11. Kishimoto T., et al. Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. Int. J. Cancer 1996, 69:290-294.
12. Lau W.M., et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014, 74:2630-2641.
13. Li L., Bhatia R. Stem cell quiescence. Clin. Cancer Res. 2011, 17:4936-4941.
14. Li D., et al. Pancreatic cancer. Lancet 2004, 363:1049-1057.
15. Li C., et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
16. Mani S.A., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
17. Mechetner E., et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer Res. 1998, 4:389-398.
18. Mielgo A., et al. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ. 2006, 13:465-477.
19. Miletti-González K.E., et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res. 2005, 65:6660-6667.
20. Mima K., et al. CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 2012, 72:3414-3423.
21. Miyatake Y., et al. Protective roles of epithelial cells in the survival of adult T-cell leukemia/lymphoma cells. Am. J. Pathol. 2013, 182:1832-1842.
22. Okabe H., et al. CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma. Br. J. Cancer 2014, 110:958-966.
23. Sai Y., et al. Bile acid secretion and direct targeting of mdr1-green fluorescent protein from Golgi to the canalicular membrane in polarized WIF-B cells. J. Cell Sci. 1999, 112(Pt 24):4535-4545.
24. Schiel J.A., et al. Endocytic transport and cytokinesis: from regulation of the cytoskeleton to midbody inheritance. Trends Cell Biol. 2013, 23:319-327.
25. Su Y.J., et al. Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J. 2011, 30:3186-3199.
26. Vuoriluoto K., et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011, 30:1436-1448.
27. Wang Z., et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
28. Wellner U., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11:1487-1495.
29. Yamaguchi A., et al. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J. Clin. Oncol. 1996, 14:1122-1127.
30. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119:1429-1437.
31. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 2011, 11:254-267.